Thesesymptoms are commonly observed in CF patients at baseline and approximately10% of patients reported worsening psychological symptoms and sleepdisorders after starting Elexacaftor-Tezacaftor-Ivacaftor (ETI).−, , ,  Disruption of the SCCPDH function by VX-445, a component of ETI,could possibly be associated with this outcome (Figure ). Here, SCCPDH is linked to cystic fibrosis.